Article R. 22-10-23 of the French Commercial Code Market : Euronext ParisISIN code / Mnemo : FR0013233012 / IVAWeb site : www.inventivapharma.com  DateNumber of Shares Outstanding Total voting rights,...
Inventia's Generic Chlorthalidone Receives Approval in the U.S.
Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS) and other diseases with significant unmet medical need, today announced the half-year report of its liquidity contract with Kepler Cheuvreux.
 Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS) and other diseases with significant unmet medical need, today announced the half-year report of its liquidity contract with Kepler Cheuvreux.
Inventia Healthcare Generic Colesevelam HCl Receives Approval in US
Inventia Healthcare Generic Rosuvastatin Calcium Receives Approval in US
Inventia Healthcare Generic Venlafaxine Hydrochloride Receives Approval in US
Inventia Healthcare Generic Olmesartan medoximil Receives Approval in US Inventia Healthcare Generic Venlafaxine Hydrochloride Receives Approval in US
Inventia Hlthcare’s Generic TolterodineTartrate Receives Approval In US
Inventia Healthcare`s Generic Paliperidone Receives Approval in US